Crystalys Therapeutics Stock

HealthTech

Operator of a biopharmaceutical company intended to address the significant unmet medical needs of people living with gout. The company develops and commercializes dotinurad, a next-generation URAT1 inhibitor for the treatment of gout, enabling healthcare providers to improve the management of hyperuricemia and gout.